Nonetheless, hope may be on the horizon with newer systemic adjuvant immunotherapeutic agents (temozolomide plus cisplatin) for resected MM, which has shown better over-all survival (p < 0.01) and relapse-free survival (p < 0.001), when compared to surgery alone or with surgery and high dose interferon IFN-α2b [25]. The gene discussed is IFNA2; the disease is Miyoshi myopathy.